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IN VIVO DOSIMETRY AND IMRT
Marinello G.
Unite de Radiophysique et Radioprotection,
Hopital Henri Mondor
Numerous international and national
organizations (CIPR 1985, WHO 1988,
SFPH-SFRO 1992, AAPM 1994, ESTRO
1994, IAEA 1998, IMRT Collaborative
Group 2001 ...) recommend the practice of
in vivo dosimetry to check the global
quality of treatments by radiotherapy. This
type of dosimetry is much more difficult to
carry out for IMRT than for standard
treatments because of the numerous and
inhomogeneous beams involved (with low
dose segments and high dose gradients),
and the heterogeneity of dose within the
target volume. After having recalled the
main objectives of in vivo dosimetry
(detection of errors and dose verification),
a quick review of dosimetric detectors
susceptible to answer to problems of IMRT
is made. They should be sensitive under a
small volume, not connected to high
voltage for patient security, with a res-
ponse accurate, reproducible, independent
on dose-rate, beam direction, temperature
at least up to 42°C, and of course, be
tissue-equivalent with a low energy depen-
dence. The characteristics, advantages
and disadvantages of different detectors
such as diodes, MOSFETs, thermolu-
minescent detectors (TLD), radiochromic
films Gafchromic HS and scintillator plastic
are reviewed. Considering the particu-
larities of them, it seems that TLD be the
best suited for practice of in vivo dosimetry
in IMRT. Some examples of application
will be presented to illUstrate that They
show that tolerance values different from
those accepted for standard radiotherapy
and suited to IMRT is mandatory for a
correct exploitation of the obtained
Results. The conclusion is that practice of
in vivo dosimetry during IMRT is possible
but delicate, that TLD dosimetry is the best
suited to it but time-consuming and
relatively expansive, so that it should be
restricted to selected applications in the
frame of strict protocols in order to
optimize results and cost.
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THE ROLE OF THE SECONDARY
STANDARD DOSIMETRY LABORA-
TORY IN THE QUALITY ASSURAN-
CE IN RADIOTHERAPY IN POLAND
Gwiazdowska B., Bulski W.
Center of Oncology, Roentgen str. 5,
02-781 Warsaw, Poland
In Poland, in 1937, a special measu-
rement unit was established in the Radium
Institute (former name of the Institute of
Oncology). The continuation of this unit is
the SSDL, which was established in 1966
at the Medical Physics Department (MPD)
of the Institute of Oncology. In 1988, the
Laboratory was approved as a member of
the IAEAlWHO SSDL network, and is
periodically audited by the IAEA. The
SSDL plays an important role in maintai-
ning proper dosimetry standards in radio-
therapy in Poland.
The main activities of the SSDL are:
- Collecting data concerning the infrastru-
cture of radiotherapy in Poland. This
activity started in 1993 and is continued
on the yearly basis.
- Calibration of dosimeters at the national
level; it started as early as 1937. The
SSDL calibrates over 20 ionisation
chambers each year. The Co-60
exposure calibration factors are
established, and then the air-kerma and
the absorbed dose calibration factors are
calculated. The system linearity and
energy characteristics are determined in
the orthovoltage range. In 2002 the
measurement facility for calibrating the
mammography dosimeters was set-up.
- External qualify audits . of ,dosimetry in
radiotherapy centres in Poland. During
the period 1991-2001, 151 audits, based
on TLD dose inter-comparisons were
performed in reference conditions. The
deviations above 3.5% (defined as acce-
ptance level) were observed in 18 cases
(nearly 12%). Since 2002 the audits in
more complex, non standard conditions
started.
- Preparation of protocols and recommen-
dations on dosimetry in radiotherapy.
The QC recommendations for Co-60
units and accelerators were issued
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(brachytherapy has been taken care of
by the Centre of Oncology in Cracow).
The QC- recommendations for simula-
tors and CT-scanners are in preparation.
Training of physicists and radiotherapists
(including the participants from other
East European countries) in order to
adhere to the increasing complexity of
modern radiotherapy procedures.
Trainings are performed individually or in
a form of courses. This activity follows
the recommendations of the Euroatom
Directive 97/43 on health protection of
individuals against the dangers of
ionizing radiation in relation to medical
exposure.
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CELLULAR SURVIVAL AS
THE COMMON DENOMINATOR
BETWEEN HEAVY-ION AND
PHOTON BEAM RADIOTHERAPY
Walig6rski M.P.R.1,2, Lesiak J.1
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Experimental data on cellular survival in
vitro often serve as a radiobiological basis
for modeling and interpreting the clinical
results of "classical" cancer radiotherapy,
using external photon and electron beams.
Since the radiobiological effectiveness
(RBE) of such beams is 1, the isodose
distribution, the basis for optimizing the
radiotherapy planning procedure, could
readily be interpreted as the distribution of
surviving cells in the tumour region, if a
suitable radiobiological model were
available. In the case of heavy-ion beam
radiotherapy where various techniques are
used to spread the Bragg peak over the
tumour volume, RBE is known to vary
widely along·the depth of the beam, and to
depend on many parameters, such as the
physical characteristics of the ion beam
(particle energy-fluence depth distribution,
ion charge, dose or fluence of initial
particles) and the radiobiological descrip-
tors of tumour and healthy tissue cell lines
(characterized, e.g., by in vitro survival
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curves and appropriate RBE-LET depen-
dences). To clinically evaluate results of
heavy-ion radiotherapy, typically, a "clinical
RBE" value is sought - a single factor by
which the physical dose of the heavy ions
should be multiplied to equate the clinical
effect of the "classical" (Le. photon or
electron) and heavy ion beam modalities,
in a similar clinical situation. The cellular
track structure theory developed by Katz
and co-workers, a four-parameter analy-
tical model, has been extremely successful
in quantitatively describing and predicting
RBE for cellular survival in vitro after
heavy ion bombardment, whereby RBE is
referred to a beam of Co-GO gamma rays.
Survival curves after a dose from a beam
of heavy ions (specified by the charge,
energy and fluence of these ions) can be
calculated, once the four parameters have
been simUltaneously fitted to a set of
experimentally measured cellular survival
curves. While the basic track structure
calculation concerns "track-segment" irra-
diation, the model provides for mixed-field
irradiation along the beam depth, thus cell
survival-beam depth dependences can be
readily calculated for realistic treatment
conditions, as a function of initial particle
fluence (representing entrance dose), say,
at the patient's skin. Thus, rather than
multiply the local dose from heavy ions by
an appropriate value of RBE to arrive at
"iso-biological dose" distributions, iso-
survival distributions after "conventional"
treatment (represented in the model by a
Co-GO beam) and after treatment with
beams of heavy charged particles, may be
compared. This approach and its possible
advantages against the usual comparison
of "physical dose*RBE = biological dose"
distributions, will be discussed.
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